PriceTargets.com logo

Medexus Pharmaceuticals - MDP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$5.25
  • Forecasted Upside: 86.83%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 2 Strong Buy Ratings
C$2.81 As of 12/18/2024 01:44 PM ET
▲ +0.01 (0.36%)

This chart shows the closing price for MDP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medexus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDP

Analyst Price Target is C$5.25
▲ +86.83% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Medexus Pharmaceuticals in the last 3 months. The average price target is C$5.25, with a high forecast of C$8.25 and a low forecast of C$3.50. The average price target represents a 86.83% upside from the last price of C$2.81.

This chart shows the closing price for MDP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Medexus Pharmaceuticals. This rating changed within the last month from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 2 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/20/2024Raymond JamesUpgradeMarket Perform ➝ OutperformC$3.00 ➝ C$4.00
9/30/2024Leede FinancialSet TargetSpeculative BuyC$8.25
8/22/2024Stifel NicolausBoost TargetBuyC$3.00 ➝ C$3.50
8/12/2024Stifel CanadaUpgradeModerate Buy ➝ Strong-Buy
8/9/2024Stifel NicolausBoost TargetSpeculative Buy ➝ BuyC$2.35 ➝ C$2.80
6/26/2024Ventum Cap MktsUpgradeStrong-Buy
2/22/2024Stifel NicolausLower TargetC$2.85 ➝ C$2.35
10/17/2023Raymond JamesSet TargetOutperformC$4.00
8/14/2023Stifel NicolausBoost TargetC$1.80 ➝ C$3.50
6/26/2023Bloom BurtonUpgradeHold ➝ Buy
6/23/2023Stifel NicolausUpgradeHold ➝ Speculative Buy
3/10/2023Raymond JamesBoost TargetOutperformC$3.50 ➝ C$4.00
2/10/2023Raymond JamesLower TargetOutperformC$4.00 ➝ C$3.50
2/10/2023Canaccord Genuity GroupBoost TargetC$3.00 ➝ C$4.00
2/10/2023Stifel NicolausDowngradeBuy ➝ Hold
11/10/2022Raymond JamesUpgradeMarket Perform ➝ OutperformC$2.00 ➝ C$4.00
10/7/2022Canaccord Genuity GroupBoost TargetC$2.75 ➝ C$3.00
9/22/2022Canaccord Genuity GroupLower TargetC$3.50 ➝ C$2.75
9/20/2022Raymond JamesDowngradeOutperform ➝ Market PerformC$4.50 ➝ C$2.00
8/10/2022Stifel NicolausLower TargetC$14.25 ➝ C$11.00
7/26/2022Raymond JamesSet TargetOutperformC$4.50
3/2/2022Raymond JamesBoost TargetOutperformC$5.50 ➝ C$5.75
2/22/2022Raymond JamesSet TargetOutperformC$5.50
2/23/2021Bloom BurtonUpgradeAccumulate ➝ Buy
(Data available from 12/18/2019 forward)

News Sentiment Rating

1.33 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Medexus Pharmaceuticals logo
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.
Read More

Today's Range

Now: C$2.81
Low: C$2.81
High: C$2.86

50 Day Range

MA: C$2.53
Low: C$1.96
High: C$3.05

52 Week Range

Now: C$2.81
Low: C$1.47
High: C$3.27

Volume

2,677 shs

Average Volume

40,516 shs

Market Capitalization

C$68.93 million

P/E Ratio

56.00

Dividend Yield

N/A

Beta

1.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Medexus Pharmaceuticals?

The following Wall Street analysts have issued research reports on Medexus Pharmaceuticals in the last twelve months: Leede Financial, Raymond James, Stifel Canada, Stifel Nicolaus, and Ventum Cap Mkts.
View the latest analyst ratings for MDP.

What is the current price target for Medexus Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Medexus Pharmaceuticals in the last year. Their average twelve-month price target is C$5.25, suggesting a possible upside of 86.8%. Leede Financial has the highest price target set, predicting MDP will reach C$8.25 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of C$3.50 for Medexus Pharmaceuticals in the next year.
View the latest price targets for MDP.

What is the current consensus analyst rating for Medexus Pharmaceuticals?

Medexus Pharmaceuticals currently has 3 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDP will outperform the market and that investors should add to their positions of Medexus Pharmaceuticals.
View the latest ratings for MDP.

What other companies compete with Medexus Pharmaceuticals?

Other companies that are similar to Medexus Pharmaceuticals include Supreme Cannabis, ESSA Pharma, Organigram, ICC Labs and RIV Capital. Learn More about companies similar to Medexus Pharmaceuticals.

How do I contact Medexus Pharmaceuticals' investor relations team?

Medexus Pharmaceuticals' physical mailing address is 35 Nixon Road, Unit 1, Bolton, ON L7E 1K1, Canada. The company's listed phone number is 877-633-3987. The official website for Medexus Pharmaceuticals is www.medexus.com. Learn More about contacing Medexus Pharmaceuticals investor relations.